Increasing Potency and Price of Cannabis in Europe, 2006-16

Overview

Journal Addiction

Specialty Psychiatry

Date 2019 Jan 1

PMID 30597667

Citations 40

Authors

Tom P Freeman

Teodora Groshkova

Andrew Cunningham

Roumen Sedefov

Paul Griffiths

Michael T Lynskey

Affiliations

Soon will be listed here.

Abstract

Aims: To quantify changes in (i) potency (concentration of Δ -tetrahydrocannabinol; %THC), (ii) price (euros/g of cannabis) and (iii) value (mg THC/euro) of cannabis resin and herbal cannabis in Europe.

Design: Repeated cross-sectional study.

Setting And Participants: Data collected from 28 European Union (EU) member states, Norway and Turkey by the European Monitoring Centre for Drugs and Drug Addiction.

Measurements: Outcome variables were potency, price and value for cannabis resin and herbal cannabis in Europe, 2006-16. Inflation was estimated using the Harmonised Indices of Consumer Prices. Mixed-effects linear regression models were used to estimate linear and quadratic time trends, with a random intercept and slope fitted to account for variation across countries.

Findings: Resin potency increased from a mean [95% confidence interval (CI)] of 8.14% THC (6.89, 9.49) in 2006 to 17.22 (15.23, 19.25) in 2016. Resin price increased from 8.21 euros/g (7.54, 8.97) to 12.27 (10.62, 14.16). Resin increased in value, from 11.00 mg THC per euro (8.60, 13.62) to 16.39 (13.68, 19.05). Quadratic time trends for resin potency and value indicated minimal change from 2006 to 2011, followed by marked increases from 2011 to 2016. Herbal cannabis potency increased from 5.00% THC (3.91, 6.23) to 10.22 (9.01, 11.47). Herbal price increased from 7.36 euros/g (6.22, 8.53) to 12.22 (10.59, 14.03). The value of herbal cannabis did not change from 12.65 mg of THC per euro (10.18, 15.34) to 12.72 (10.73, 14.73). All price trends persisted after adjusting for inflation.

Conclusions: European cannabis resin and herbal cannabis increased in potency and price from 2006 to 2016. Cannabis resin (but not herbal cannabis) increased in the quantity of Δ -tetrahydrocannabinol per euro spent. Marked increases in resin potency and value from 2011 to 2016 are consistent with the emergence of new resin production techniques in European and neighbouring drug markets.

Citing Articles

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.

Austin-Zimmerman I, Spinazzola E, Quattrone D, Wu-Choi B, Trotta G, Li Z Psychol Med. 2024; :1-13.

PMID: 39637925 PMC: 11650186. DOI: 10.1017/S0033291724002058.

Clinical Evaluation of the Cannabis-Using Patient: A Moving Target.

Radparvar S Perm J. 2024; 28(4):77-86.

PMID: 39466129 PMC: 11648329. DOI: 10.7812/TPP/24.088.

Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations.

Freeman T, Beeching E, Craft S, Di Forti M, Frison G, Lindholst C Eur Arch Psychiatry Clin Neurosci. 2024; 275(2):421-429.

PMID: 38771330 DOI: 10.1007/s00406-024-01816-w.

Incident psychotic experiences following self-reported use of high-potency cannabis: Results from a longitudinal cohort study.

Hines L, Heron J, Zammit S Addiction. 2024; 119(9):1629-1634.

PMID: 38736320 PMC: 7616847. DOI: 10.1111/add.16517.

Brain reward function in people who use cannabis: a systematic review.

Beyer E, Poudel G, Antonopoulos S, Thomson H, Lorenzetti V Front Behav Neurosci. 2024; 17:1323609.

PMID: 38379938 PMC: 10877725. DOI: 10.3389/fnbeh.2023.1323609.

References

Romer Thomsen K, Callesen M, Feldstein Ewing S . Recommendation to reconsider examining cannabis subtypes together due to opposing effects on brain, cognition and behavior. Neurosci Biobehav Rev. 2017; 80:156-158. PMC: 6373765. DOI: 10.1016/j.neubiorev.2017.05.025. View

van der Pol P, Liebregts N, de Graaf R, Korf D, van den Brink W, van Laar M . Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend. 2013; 133(2):352-9. DOI: 10.1016/j.drugalcdep.2013.06.009. View

Englund A, Freeman T, Murray R, McGuire P . Can we make cannabis safer?. Lancet Psychiatry. 2017; 4(8):643-648. DOI: 10.1016/S2215-0366(17)30075-5. View

van der Pol P, Liebregts N, de Graaf R, Korf D, van den Brink W, van Laar M . Validation of self-reported cannabis dose and potency: an ecological study. Addiction. 2013; 108(10):1801-8. DOI: 10.1111/add.12226. View

Englund A, Morrison P, Nottage J, Hague D, Kane F, Bonaccorso S . Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2012; 27(1):19-27. DOI: 10.1177/0269881112460109. View

Freeman T, Swift W . Cannabis potency: the need for global monitoring. Addiction. 2015; 111(2):376-7. DOI: 10.1111/add.13207. View

Pijlman F, Rigter S, Hoek J, Goldschmidt H, Niesink R . Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol. 2005; 10(2):171-80. DOI: 10.1080/13556210500123217. View

Cascini F, Aiello C, Di Tanna G . Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev. 2011; 5(1):32-40. DOI: 10.2174/1874473711205010032. View

Zamengo L, Frison G, Bettin C, Sciarrone R . Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal. 2014; 7(3):255-8. DOI: 10.1002/dta.1690. View

10.

Meier M . Associations between butane hash oil use and cannabis-related problems. Drug Alcohol Depend. 2017; 179:25-31. DOI: 10.1016/j.drugalcdep.2017.06.015. View

11.

Wilson J, Freeman T, Mackie C . Effects of increasing cannabis potency on adolescent health. Lancet Child Adolesc Health. 2018; 3(2):121-128. DOI: 10.1016/S2352-4642(18)30342-0. View

12.

Raber J, Elzinga S, Kaplan C . Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci. 2015; 40(6):797-803. DOI: 10.2131/jts.40.797. View

13.

Freeman T, Winstock A . Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015; 45(15):3181-9. PMC: 4611354. DOI: 10.1017/S0033291715001178. View

14.

Smart R, Caulkins J, Kilmer B, Davenport S, Midgette G . Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. 2017; 112(12):2167-2177. PMC: 5673542. DOI: 10.1111/add.13886. View

15.

Freeman T, van der Pol P, Kuijpers W, Wisselink J, Das R, Rigter S . Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychol Med. 2018; 48(14):2346-2352. DOI: 10.1017/S0033291717003877. View

16.

de Meijer E, Bagatta M, Carboni A, Crucitti P, Moliterni V, Ranalli P . The inheritance of chemical phenotype in Cannabis sativa L. Genetics. 2003; 163(1):335-46. PMC: 1462421. DOI: 10.1093/genetics/163.1.335. View

17.

Kelly T, Foltin R, Emurian C, FISCHMAN M . Are choice and self-administration of marijuana related to delta 9-THC content?. Exp Clin Psychopharmacol. 1997; 5(1):74-82. DOI: 10.1037//1064-1297.5.1.74. View

18.

Freeman T, Morgan C, Hindocha C, Schafer G, Das R, Curran H . Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?. Addiction. 2014; 109(10):1686-94. DOI: 10.1111/add.12634. View

19.

Bedi G, Lindquist M, Haney M . An fMRI-Based Neural Signature of Decisions to Smoke Cannabis. Neuropsychopharmacology. 2015; 40(12):2657-65. PMC: 4864661. DOI: 10.1038/npp.2015.135. View

20.

Boggs D, Nguyen J, Morgenson D, Taffe M, Ranganathan M . Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ-Tetrahydrocannabinol. Neuropsychopharmacology. 2017; 43(1):142-154. PMC: 5719112. DOI: 10.1038/npp.2017.209. View